Last reviewed · How we verify
NCT03379844
HEPAR Primary: Holmium-166-radioembolization in Hepatocellular Carcinoma Patients
Phase 2 trial testing Holmium-166 radioembolization in Hepatocellular Carcinoma in 30 participants. Completed in 1 August 2021.
1 January 2020
Quick facts
| Lead sponsor | UMC Utrecht |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 21 August 2017 |
| Primary completion | 1 January 2020 |
| Estimated completion | 1 August 2021 |
| Sites | 2 locations across Netherlands |
Drugs / interventions tested
- Holmium-166 radioembolization
Conditions studied
- Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
- Hepatocellular Carcinoma Non-resectable — all drugs for Hepatocellular Carcinoma Non-resectable →
Sponsor
UMC Utrecht — full company profile →
Who can join
18 and older, any sex, with Hepatocellular Carcinoma or Hepatocellular Carcinoma Non-resectable. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients with hepatocellular carcinoma often die from intrahepatic disease since current treatment options are generally limited. Local treatment using holmium radioembolization could offer an effective treatment and a more personal approach than yttrium radioembolization (standard-of-care) as holmium has more imaging options.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
The various therapeutic applications of the medical isotope holmium-166: a narrative review.
Klaassen NJM, Arntz MJ, Gil Arranja A, Roosen J, et al · · 2019 · cited 52× · PMID 31659560 · DOI 10.1186/s41181-019-0066-3 -
Holmium-166 Radioembolization: Current Status and Future Prospective.
Stella M, Braat AJAT, van Rooij R, de Jong HWAM, et al · · 2022 · cited 40× · PMID 35729423 · DOI 10.1007/s00270-022-03187-y -
Safety and Efficacy of <sup>166</sup>Ho Radioembolization in Hepatocellular Carcinoma: The HEPAR Primary Study.
Reinders MTM, van Erpecum KJ, Smits MLJ, Braat AJAT, et al · · 2022 · cited 30× · PMID 35589409 · DOI 10.2967/jnumed.122.263823 -
Holmium-166 radioembolisation dosimetry in HCC.
Reinders MTM, Braat AJAT, van Erpecum KJ, de Bruijne J, et al · · 2025 · cited 5× · PMID 39470786 · DOI 10.1007/s00259-024-06940-2 -
Hepatobiliary scintigraphy and liver function changes in patients with hepatocellular carcinoma treated with <sup>166</sup>Ho-radioembolization : HBS in HCC treated with holmium-166.
Reinders MTM, Smits MJL, van Erpecum K, de Bruijne J, et al · · 2025 · cited 2× · PMID 39786516 · DOI 10.1186/s13550-025-01196-9 -
Advancements in the investigation of radioactive microspheres for brachytherapy.
Jiang X, Chen L, Xu X. · · 2025 · PMID 40741536 · DOI 10.3389/fbioe.2025.1621418
Verify or expand the search:
- PubMed search for NCT03379844
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Holmium-166 radioembolization
Trials testing the same drug.
- NCT05114148 — Individualized Dosimetry for Holmium-166-radioembolization in Patients With Unresectable Hepatocellular Carcinoma · NA · unknown
Other recruiting trials for Hepatocellular Carcinoma
Currently open trials in the same condition.
- NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
- NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
- NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting
Other UMC Utrecht trials
Trials by the same sponsor.
- NCT07512336 — A Randomized Intra-Patient Controlled Trial of MagnetOs™ Putty vs Autograft in Instrumented Posterolateral Spinal Fusion · NA · not yet recruiting
- NCT07485985 — Coronary Sinus Reducer Therapy for Persisting Angina · NA · not yet recruiting
- NCT07449052 — Comprehensive Invasive Physiological Evaluation of Obstructive Coronary Artery Disease · NA · not yet recruiting
- NCT05375708 — Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Me · Phase 2 · suspended
- NCT06898541 — Coronary Sinus Reducer in Coronary Microvascular Disease · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03379844 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by UMC Utrecht
- Last refreshed: 8 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03379844.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing